Aragen Bioscience, Inc, a leading pre-clinical contract research organization specializing in the discovery and pre-clinical development of high-value biotech and pharmaceutical products, announced today at the BIO International Convention the introduction of RapTr™ services.
San Diego, CA (PRWEB) June 20, 2017
RapTr™ Cell Line Development Services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process. The results are a highly flexible and customizable platform delivering high titers in a rapid timeframe from early stage Discovery through to the Clinic. RapTr also incorporates state-of-the-art analytical methods to characterize and evaluate product quality at all stages. As RapTr is based on CHO-DG44, it is regulatory-friendly and royalty-free.
“Building on our decades of experience in cell line development and recent investments in expanding our biologics team and facilities, we’re excited to announce RapTr. We believe that our suite of protein expression and analytical services will give our clients tremendous flexibility in developing cell lines and generating high quality proteins using a single scalable platform regardless of their stage of development,” said Oren Beske, Ph.D., President of Aragen Bioscience.
About Aragen Bioscience, Inc.
Aragen Bioscience, Inc., a wholly-owned subsidiary of GVK Biosciences (GVK BIO), is a leading contract research organization based in the San Francisco Bay Area. The company offers a diverse set of in vitro and in vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products. For additional information, please visit http://www.aragenbio.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/2017/06/prweb14439189.htm